v3.25.4

SCHEDULE OF RESTATEMENT CONSOLIDATED FINANCIAL STATEMENTS (Details) (Parenthetical) - $ / shares	Sep. 30, 2025	Dec. 31, 2024	Dec. 31, 2023
Common stock par value	$ 0.0001	$ 0.0001
Aspire Biopharma Inc [Member]
Common stock par value		$ 0.00005	$ 0.00005
Revision of Prior Period, Adjustment [Member] | Aspire Biopharma Inc [Member]
Common stock par value			$ 0.001

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

X

- Details

Name:	srt_ConsolidatedEntitiesAxis=ASBP_AspireBiopharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RestatementAxis=srt_RestatementAdjustmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: